Do analysts recommend PRFX or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRFX or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A

Which has preferable earnings and valuation, NKGN or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is NKGN or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Ampio Pharmaceuticals N/A N/A N/A

Do analysts rate AMPE or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate JAGX or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is JAGX or AMPE more profitable?

Ampio Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%. Company Net Margins Return on Equity Return on Assets Jaguar Animal Health -187.88% N/A -131.45% Ampio Pharmaceuticals N/A N/A N/A

Which has stronger valuation and earnings, BPTSY or AMPE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is BPTSY or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A

Ampio Pharmaceuticals (AMPE) Competitors

$0.18 0.00 (0.00%)

As of 08/20/2026

Compare

AMPE vs. PRFX, NKGN, IMCC, JAGX, and BPTSY

Should you buy Ampio Pharmaceuticals stock or one of its competitors? Ampio Pharmaceuticals's main competitors and comparable companies include PainReform (PRFX), NKGen Biotech (NKGN), IM Cannabis (IMCC), Jaguar Animal Health (JAGX), and Biophytis (BPTSY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ampio Pharmaceuticals compare to PainReform?

PainReform (NASDAQ:PRFX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	N/A

In the previous week, PainReform's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
Ampio Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PainReform has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market.

37.3% of PainReform shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PainReform has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	43.37	-$5.02M	-$736.66	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Summary

PainReform beats Ampio Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NKGen Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Ampio Pharmaceuticals	N/A	N/A	N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
NKGen Biotech	Neutral
Ampio Pharmaceuticals	Neutral

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Summary

NKGen Biotech beats Ampio Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to IM Cannabis?

Ampio Pharmaceuticals (NYSE:AMPE) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Ampio Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
IM Cannabis	$45.80M	0.02	-$8.10M	-$2.02	N/A

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, IM Cannabis had 3 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 beat IM Cannabis' score of -0.50 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
IM Cannabis	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ampio Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Ampio Pharmaceuticals' return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
IM Cannabis	-39.62%	-585.96%	-58.32%

Summary

IM Cannabis beats Ampio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 0.2% of Jaguar Animal Health shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ampio Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.05	-$53.43M	-$591.92	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Ampio Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Ampio Pharmaceuticals	N/A	N/A	N/A

Jaguar Animal Health has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Jaguar Animal Health had 3 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 3 mentions for Jaguar Animal Health and 0 mentions for Ampio Pharmaceuticals. Jaguar Animal Health's average media sentiment score of 0.88 beat Ampio Pharmaceuticals' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Jaguar Animal Health	Positive
Ampio Pharmaceuticals	Neutral

Summary

Jaguar Animal Health and Ampio Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	N/A

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Ampio Pharmaceuticals	Neutral

Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPE vs. The Competition

Export

Metric	Ampio Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$208K	$12.44B	$7.27B	$24.12B
Dividend Yield	N/A	2.64%	2.54%	3.71%
P/E Ratio	-0.02	784.87	270.68	30.15
Price / Sales	N/A	761.74	639.40	24.35
Price / Cash	N/A	92.12	76.89	32.42
Price / Book	0.05	11.85	13.43	6.77
Net Income	-$8.63M	$2.80B	$3.46B	$1.07B
7 Day Performance	N/A	1.92%	2.15%	-0.62%
1 Month Performance	N/A	3.69%	6.18%	2.47%
1 Year Performance	N/A	6.57%	24.96%	14.88%

Ampio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PRFX PainReform	0.203 of 5 stars	$1.01 +7.3%	N/A	-87.8%	$820K	$20K	N/A	4
NKGN NKGen Biotech	N/A	$0.01 flat	N/A	N/A	$666K	N/A	N/A	N/A
IMCC IM Cannabis	0.1465 of 5 stars	$0.11 +1.0%	N/A	-94.8%	$650K	$39.17M	N/A	340
JAGX Jaguar Animal Health	0.7885 of 5 stars	$0.92 -5.3%	N/A	-98.6%	$590K	$11.51M	N/A	50	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRFX, NKGN, IMCC, JAGX, and BPTSY

How does Ampio Pharmaceuticals compare to PainReform?

Summary

How does Ampio Pharmaceuticals compare to NKGen Biotech?

Summary

How does Ampio Pharmaceuticals compare to IM Cannabis?

Summary

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRFX, NKGN, IMCC, JAGX, and BPTSY

How does Ampio Pharmaceuticals compare to PainReform?

Is PRFX or AMPE more profitable?

Does the media refer more to PRFX or AMPE?

Do analysts recommend PRFX or AMPE?

Which has more risk & volatility, PRFX or AMPE?

Do insiders & institutionals have more ownership in PRFX or AMPE?

Which has preferable valuation & earnings, PRFX or AMPE?

Summary

How does Ampio Pharmaceuticals compare to NKGen Biotech?

Do institutionals & insiders hold more shares of NKGN or AMPE?

Which has more volatility & risk, NKGN or AMPE?

Is NKGN or AMPE more profitable?

Does the media favor NKGN or AMPE?

Which has preferable earnings and valuation, NKGN or AMPE?

Summary

How does Ampio Pharmaceuticals compare to IM Cannabis?

Which has more volatility and risk, AMPE or IMCC?

Which has better valuation and earnings, AMPE or IMCC?

Do insiders and institutionals hold more shares of AMPE or IMCC?

Does the media refer more to AMPE or IMCC?

Do analysts rate AMPE or IMCC?

Is AMPE or IMCC more profitable?

Summary

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Do insiders & institutionals have more ownership in JAGX or AMPE?

Which has preferable earnings and valuation, JAGX or AMPE?

Is JAGX or AMPE more profitable?

Which has more risk and volatility, JAGX or AMPE?

Do analysts rate JAGX or AMPE?

Does the media refer more to JAGX or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Which has stronger valuation and earnings, BPTSY or AMPE?

Is BPTSY or AMPE more profitable?

Does the media refer more to BPTSY or AMPE?

Which has more risk & volatility, BPTSY or AMPE?

Do insiders and institutionals have more ownership in BPTSY or AMPE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools